title: Recent developments on dry eye disease treatment compounds.
abstract: Dry eye syndrome is a common tears and ocular surface multifactorial disease, described by changes in the ocular surface epithelia related to reduced tears quantity and ocular surface sensitivity, leading to inflammatory reaction. Managing the eye inflammation proved helpful to patients with dry eye disease and current treatment is based on the use of topically applied artificial tear products/lubricants, tear retention management, stimulation of tear secretion and using anti-inflammatory drugs. In this article we revise the corresponding literature and patents assembling the new treatment approaches of novel and future pharmaceutical compounds destined for the dry eye disease treatment. The most frequent categories of compounds presented are secretagogues and anti-inflammatory drugs. These compounds are the research outcome of novel therapeutic strategies designed to reduce key inflammatory pathways and restore healthy tear film.
authors: Departamento de Bioquímica y Biología Molecular IV, Facultad de Óptica y Optometría, Universidad Complutense de Madrid, C/Arcos de Jalón 118, 28037 Madrid, Spain.
authors: Basilio
authors: B
authors: Colligris
authors: Departamento de Bioquímica y Biología Molecular IV, Facultad de Óptica y Optometría, Universidad Complutense de Madrid, C/Arcos de Jalón 118, 28037 Madrid, Spain.
authors: Hanan Awad
authors: HA
authors: Alkozi
authors: Departamento de Bioquímica y Biología Molecular IV, Facultad de Óptica y Optometría, Universidad Complutense de Madrid, C/Arcos de Jalón 118, 28037 Madrid, Spain.
authors: Jesus
authors: J
authors: Pintor
keywords: Anti-inflammatory; Dry eye; Keratitis sicca; Keratoconjunctivitis sicca; Mucin secretion; NSAID; Tear secretion; Xerophthalmia